"Moderna posted a sizable Q1 2026 beat on May 1, with revenue of $389 million against the $236.36 million consensus. Management reaffirmed full-year guidance for up to 10% revenue growth and a year-end cash position of $4.5 bil"
Moderna shares rose roughly 6% to around $57.52 after ending Friday near $54.35, extending a strong 2026 performance. The move outpaced Pfizer and Novavax during the same session, and Moderna led year-to-date gains with about 95% versus 50% for Novavax and 5% for Pfizer. Hantavirus-related headlines tied to a cruise ship outbreak renewed attention on Moderna’s early-stage mRNA Hantavirus vaccine research, drawing retail traders back to the stock. Hantavirus is rodent-borne and can cause Hantavirus Pulmonary Syndrome with potentially high fatality rates, though outbreaks have historically been geographically contained. Some investors questioned whether the catalyst can translate into near-term revenue, while others pointed to biotech rotation and technical strength. Recent fundamentals included a Q1 2026 revenue beat and reaffirmed guidance, with year-end cash projected around $4.5 billion.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]